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Abstract
Specific tyrosine kinase inhibitors (TKIs) are rapidly developing clinical tools applied for the inhibition of malignant cell growth and
metastasis formation. Most of these newly developed TKI molecules are hydrophobic, thus rapidly penetrate the cell membranes to reach
intracellular targets. However, a large number of tumor cells overexpress multidrug transporter membrane proteins, which efficiently extrude
hydrophobic drugs and thus may prevent the therapeutic action of TKIs. In the present work, we demonstrate that the most abundant and
effective cancer multidrug transporters, MDR1 and MRP1, directly interact with several TKIs under drug development or already in clinical
trials. This interaction with the transporters does not directly correlate with the hydrophobicity or molecular structure of TKIs, and shows a
large variability in transporter selectivity and affinity. We suggest that performing enzyme- and cell-based multidrug transporter interaction
tests for TKIs may greatly facilitate drug development, and allow the prediction of clinical TKI resistance based on this mechanism.
Moreover, diagnostics for the expression of specific multidrug transporters in the malignant cells, combined with information on the
interactions of the drug transporter proteins with TKIs, should allow a highly effective, individualized clinical treatment for cancer patients.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Carcinogenesis in numerous cases is based on a patho-
logical intracellular signal transduction, in which the acti-
vation of specific tyrosine kinases plays a major role.
Tyrosine kinases modify highly diverse cellular responses,
including proliferation, differentiation, cell–cell interac-
tions, or cell motility, thus aberrant TK activity leads to
various disease states. Many oncogenes found in cancers are
derived from tyrosine kinase genes that have been deregu-
lated, leading to constitutive activity. Overexpression or
activation of wild-type tyrosine kinases can also lead to
cancer (see reviews [1–3]).
Tyrosine kinase inhibitors (TKI) with increased specific-
ity and selectivity have been developed against misregulated
or unregulated receptor-dependent and intracellular tyrosine
kinases, which play a major role in cancer development.
Modification of both tumor growth and metastatic potential
of cancer cells has been reported by such agents (see [Refs.
4,5]). Based on these results, development of specific
inhibitors of selected tyrosine kinases became a major area
of modern antitumor drug research.
A prominent recent example for a successful antitumor
application of TKIs is the development of specific Abl
TKIs. The permanent activation or overexpression of the
Abl cytosolic tyrosine kinase has been associated with a
variety of human tumors, especially leukemias. In chronic
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myeloid leukemia (CML), the most common form of
leukemias, a 210-kDa form of the Bcr–Abl fusion protein,
resulting from a (9:22)-chromosome translocation (Phila-
delphia chromosome), is present in 95% of these patients.
The transforming function of the Bcr–Abl fusion protein
depends on the constitutive and elevated tyrosine kinase
activity of the enzyme, thus the Abl tyrosine kinase has
become a validated target for antitumor drug research.
Several effective inhibitors of the Bcr–Abl kinase have
been synthesized and introduced into preclinical trials. Data
in the literature indicate that CGP57148B (STI-571, Glee-
vee), a 2-phenylamino-pyrimidine derivative, selectively
inhibits the tyrosine kinase Abl and Bcr–Abl. It has also
been documented that this compound selectively suppresses
the growth of Bcr–Abl-positive cells over a wide dose
range, with a maximal differential effect at about 1 AM.
Inhibition of the Bcr–Abl kinase by STI-571 preferentially
inhibits the growth of immature leukemic precursor cells,
and efficiently reverts the antiapoptotic effects of Bcr–Abl
by down-regulating BCL-X [6]. According to the first
clinical trials, STI-571 treatment of CML produced haema-
tological remission in 90% of patients [7]. Further clinical
studies have ascertained a significant antitumor effectivity
of STI-571 both in CML and other cancerous diseases (see
[Ref. 8]), thus a wide range of clinical applications for these
compounds is expected in the near future.
Untoward activation of EGF receptor tyrosine kinases is
another well-documented phenomenon in a variety of
malignancies, thus a number of EGFR-TKIs have also re-
ached various phases of clinical trials (see [Ref. 9]). An
important irreversible inhibitor of the EGF receptor tyrosine
kinase (EKI-785), has been recently introduced into pre-
clinical investigations [10]. TRX-13 [11], and tyrphostins,
including AG-213, AG-1112 and AG-1393, are molecules
which were reported to inhibit various receptor-coupled
tyrosine kinases with relatively high specificity (see [Ref.
12]).
In our research group, we have developed a series of
novel TKIs with the aim of modifying cellular responses
and inhibiting cancer cell growth [13–17]. In the rational
drug design program, the synthesized molecules, examined
under proper quality control, were screened in several
enzyme-, and cell-based assays, showing significant tyro-
sine kinase modulating effects. Several of these molecules,
including OBF-1622, OBF-1822, OBF-1834, and OL-57
are currently introduced into preclinical trials.
The therapeutic potential of the TKIs, targeted against
cytosolic enzymes, depends both on specific kinase inhib-
itory potential, as well as their access to their intracellular
targets. Most of the effective TKIs are hydrophobic mole-
cules, which are rapidly absorbed, distributed, and penetrate
the cell membranes. However, the so-called multidrug
transporters, present in the physiological barriers and in a
large variety of tumor cells, may significantly alter the
bioavailability of TKIs both at the systemic and the cellular
levels.
The human multidrug transporters are plasma membrane
glycoproteins which provide a major obstacle in the efficient
chemotherapy of patients suoffering from cancer. These
transporters belong to the family of ABC proteins, and
work as ATP-dependent primary active transporters, effi-
ciently extruding the clinically applied chemotherapeutic
compounds. The two key proteins currently believed to be
involved in cancer multidrug resistance are MDR1 (P-
glycoprotein) and MRP1 (multidrug resistance protein 1).
Both of these proteins can recognize and transport a large
variety of hydrophobic drugs, and MRP1 can also extrude
anionic drugs or drug conjugates.
The exact mechanism of action of the multidrug trans-
porters is not known, although their membrane topology and
basic functional characteristics have been explored in a
variety of biochemical and cell biology studies (see [Refs.
18–20]). Multidrug transporters were first described in
drug-resistant tumor cells, but they also provide important
physiological functions: both MDR1 and MRP1 are key
players in tissue barriers, e.g. in the blood–brain barrier, and
participate in various transport and secretory functions in the
gut, liver, kidney, and several other organs. Modulators of
drug transporters are regarded as potential clinically appli-
cable agents to inhibit cancer multidrug resistance and alter
tissue distribution for various pharmacons [21,22].
Since anticancer action and general tissue distribution
for hydrophobic drugs are both significantly affected by
the multidrug transporters, by now it has been generally
accepted that cancer drug development should increase the
examination of the interaction of the lead compounds with
the multidrug transporters. In the area of TKIs, this has not
been explored as yet, although recent studies clearly
indicated the occurrence of cellular STI-571-resistance,
which may involve the function of multidrug transporters
[8].
In the present work, we have analyzed the interactions of
MDR1 and MRP1 with a variety of TKIs, including STI-
571, by using both enzyme-, and cell-based test systems.
We found that the multidrug transporters directly interacted
with several TKIs. These interactions did not directly
correlate with the hydrophobicity or molecular structure
of TKIs, and showed significant variability in selectivity
and affinity. We suggest that such studies, used in the early
stages of drug development, may significantly improve both
the selection of lead molecules and the clinical application
of TKIs.
2. Experimental procedures
2.1. Expression of MDR1 and MRP1 in insect cells
Recombinant baculoviruses containing the MDR1 and
MRP1 cDNA were prepared as described in Refs. [23,24].
Sf9 (Spodoptera frugiperda) cells were cultured and
infected with a baculovirus as described in Ref. [23].
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2.2. Membrane preparation and immunoblotting
Virus-infected Sf9 cells were harvested, their membranes
isolated and stored, and the membrane protein concentra-
tions determined, as described in Ref. [25]. Immunoblot
detection was performed and protein–antibody interaction
was determined using the enhanced chemoluminescence
technique as described earlier [24].
2.3. Membrane ATPase measurements
ATPase activity was measured basically as described in
Ref. [25] by determining the liberation of inorganic phos-
phate from ATP with a colorimetric reaction. The incubation
media contained 10 mM MgCl2, 40 mM MOPS–Tris (pH
7.0), 50 mM KCl, 5 mM DTT, 0.1 mM EDTA, 4 mM Na-
azide, 1 mM ouabain, and 4 mM ATP.
2.4. Multidrug transporter assays in mammalian cells
For the investigation of the function of MDR1 and
MRP1 in mammalian cells, we applied both well-charac-
terized transfected (NIH-3T3-MDR1, MDCKII-MDR1) and
drug-selected (HL60-MDR1, KBV1(MDR1), HL60-MRP1
(ADR), S1-MRP1, MDCKII-MRP1) cell lines, as described
in Ref. [26].
The Calcein assay, used for the quantitative determina-
tion of multidrug transporter activity, was performed as
described earlier [27,28]. In brief, fluorescence intensities
were determined in a fluorescence microplate reader after a
short in vitro incubation. Cultured and well-characterized
MDR1-Pgp expressing cells were incubated with the non-
fluorescent Calcein AM, and with the respective concen-
trations of the compounds to be examined. The increase in
cellular fluorescence, due to the liberation of free Calcein
inside the cells, was determined. MDR1- and/or MRP-
interactive compounds inhibited the outward transport of
Calcein AM, thus significantly increase the rate of Calcein
accumulation. In order to obtain the respective IC50 values
for the TKIs, a computer-based evaluation protocol was
applied.
2.5. TKIs investigated in the present study
The TKIs used in these experiments were synthesized
and characterized in our laboratory as it was published
earlier [5,13–16]. Fig. 1 shows the structural formulas for
the TKIs examined in the present experiments.
2.6. Hydrophobicity parameters
Hydrophobicity parameters for the TKIs were obtained
by two independent methods, widely used to estimate
membrane permeation of lipophilic compounds. In brief,
the logarithmic values of the octanol/water distribution for
each compound were estimated by using the Pomona data-
base and the methods named clogp http://www.daylight.
com/daycgi/clogp, based on Ref. [29]) and Kowwin (KOW-
WIN v1.55; SRC-LOGKOW for Microsoft Windows,
Copyright W. Meylan, 1993–1997), based on Ref. [30],
respectively.
3. Results
3.1. MDR1 and MRP1 ATPase activity measurements in
isolated insect cell membranes
In the first set of experiments we have examined the
effects of TKIs on the transport-related ATPase activity of
human MDR1 and MRP1 multidrug transporter proteins,
expressed in isolated insect cell membranes. The vanadate-
sensitive ATPase activity of the MDR1 multidrug trans-
porter is significantly stimulated by hydrophobic substrate
drugs [25], while the specific ATPase activity of the human
MRP1 protein is stimulated by various glutathione-conju-
gates (GS-X), glucuronate-conjugates, and anionic drugs. In
the case of MRP1, the ATPase activity is also stimulated by
some of the hydrophobic compounds, e.g. vincristine, but
this stimulation, in some cases, requires the presence of free
glutathione [31]. It has been documented in detail, that the
stimulation of the MDR1-, or MRP1-ATPase activity and its
drug concentration dependence closely correlates with the
respective transport activity of these proteins [24,25,32].
Therefore, this relatively simple assay can be used as an
efficient screening for a large number of different com-
pounds.
In order to explore all possible forms of direct TKI
interactions with the multidrug transporters, in the current
study we also examined the TKI inhibition of the MDR1
and MRP1 ATPase activities in the presence of maximum-
stimulating agents. In the case of MDR1, ATPase inhibition
by TKI was measured in the presence of 30–50 AM
verapamil, while inhibition of MRP1 was studied in the
presence of 5 mM NEM-GS. The combination of these
assays allows to distinguish among transported substrates
and inhibitors of the drug transporter proteins.
Fig. 2 documents the MDR1-ATPase measurements for
some of the compounds examined, as compared to the effect
of verapamil, as a reference compound (data for all com-
pounds are summarized in Table 1). As shown, OBF-1834,
AG-1393, OL-57, and STI-571 significantly stimulated the
MDR1-ATPase activity in the low micromolar concentration
range. TRX-13 stimulated this ATPase only in higher con-
centrations, while EKI-785 had no significant activation
effect. The different maximum levels of ATPase stimulation,
which were generally lower than that obtained with verapa-
mil (set as 100% activation), suggested that most of the
activating TKI compound may have an MDR1-ATPase
inhibitory effect in higher concentrations.
Fig. 3 shows the effect of the same compounds on the
MDR1-ATPase activity in the presence of maximally stim-
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ulating verapamil concentrations (40 AM). In this case, we
analyzed the possible inhibitory potential for the TKI
compounds. As demonstrated, AG-1393 had the most
pronounced MDR1-ATPase inhibitory effect in the low
micromolar range, and STI-571 had a slightly lower inhib-
itory potential. OBF-1834 and OL-57 acted only at concen-
trations above 20 AM, while TRX-13 had no inhibitory
effect at all. Interestingly, EKI-785 effectively inhibited the
MDR1-ATPase activity at concentrations between 10 and 20
AM.
In the following experiments, we examined the effects of
TKIs on the MRP1-ATPase activity in isolated Sf9 cell
membranes. MRP1 has a much lower ATPase activity as
compared to MDR1, and in this case we could not measure
any significant activation of the basic MRP1-ATPase activ-
ity by any of the TKIs (not shown). Interestingly, when the
MRP1-ATPase activity was maximally stimulated by 5 mM
glutathione-conjugate, NEM-GS, we observed inhibitory
actions for several compounds. As documented in Fig. 4,
we found that EK-785 inhibited the MRP1-ATPase at the
micromolar range (50% inhibition at about 10 AM), while
STI-571 had a smaller effect and only at higher concen-
trations (50% inhibition at higher than 100 AM). AG-1393
and Ol-57 were effective inhibitors, while TRX-13 had only
a partial inhibitory effect even at higher than 100 AM
concentrations.
Fig. 1. Structures of the TKIs examined in the present experiments.
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3.2. Effects of TKIs in a cellular multidrug resistance
activity (Calcein accumulation) assay
In the following experiments, we applied a whole-cell
screening system for studying the interactions of TKIs with
the multidrug transporter proteins. When cells expressing
the multidrug transporters are incubated with the non-
fluorescent Calcein AM, due to an active dye extrusion,
free Calcein accumulation is slow. MRP1 transports both
Calcein AM and free Calcein, thus the assay can be used to
study both drug transporters. Agents that interact with the
multidrug resistance proteins inhibit dye extrusion and
greatly accelerate fluorescent Calcein accumulation. The
concentration dependence of this transport inhibition
reflects the level of drug interaction with the drug pump
proteins (see Experimental procedures). The relatively sim-
ple assay and the computer-based evaluation protocol allow
the rapid in vitro screening of large numbers of agents
selectively interacting with MDR1 or MRP1, although in
this case competition or direct inhibition of the transporters
cannot be distinguished.
Fig. 5 depicts some of the results obtained with the
Calcein assay in a cell line expressing high levels of the
human MDR1 protein (HL60-MDR1). All the data obtained
for TKIs are summarized in Table 1. As shown in Fig. 5,
Calcein AM extrusion by MDR1 was significantly inhibited
by low concentrations of AG-1393, and at somewhat higher
concentrations of STI-571, OL-57, or EKI-785. OBF-1834
had an incomplete inhibitory effect, and higher concentra-
tions could not be examined, because of cellular toxicity.
TRX-13 was quite ineffective in this whole-cell-based
MDR1 assay.
Fig. 6 demonstrates a similar study for the inhibition by
TKIs of the MRP1-dependent Calcein transport in HL60-
MRP1 cells. As shown, MRP1-dependent transport was
strongly inhibited by low micromolar concentrations of
AG-1393, OBF-1834 and EKI-785, while OL-57 acted at
somewhat higher concentrations. The MRP1-dependent
transport was not significantly inhibited by TRX-13, and
only at relatively high concentrations (above 20 AM) by
STI-571.
Fig. 3. Inhibition of the verapamil-stimulated human MDR1-ATPase
activity by various concentrations of TKIs. Maximum activation (100%)
was obtained with 40 AM verapamil. Data compiled from at least four
independent measurements for each compound.
Fig. 2. Activation of the human MDR1-ATPase activity by various
concentrations of TKIs. The data are presented as relative activation values,
compared to 100% activation obtained with 40 AM verapamil (see
Experimental procedures). Data compiled from at least four independent
measurements for each compound.
Table 1
Summary of the parameters of the TKIs examined






Kinh of Calcein AM
extrusion from
HL60 MDR1 cells (AM)
Kinh of Calcein AM
extrusion from
HL60 MRP1 cells (AM)
AG-213  0.73 0.048 > 200 >200 >200 >200
OBF-1622 0.99 0.867 200 50 100 20
AG-1112 1.06 1.813 >200 >200 200 20
HDL-2722 1.29 0.439 100 >200 100 100
OBF-1822 2.19 3.551 50 100 10 10
OBF-1834 2.67 4.148 5 20 >30 4
STI-571 3.01 4.529 1 3 8 20–30
AG-1393 3.34 3.781 0.8 1 1 2
EKI-785 3.69 4.68 >200 20 20 4–5
OL-57 3.96 5.178 5 50 20 8
TRX-13 4.05 4.895 20 >200 >200 >200
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3.3. Comparison of hydrophobicity parameters and multi-
drug transporter interaction data
When using the two widely accepted methods, Kowwin
and clogp, respectively, to obtain hydrophobicity parameters
(see Experimental procedures) for the TKIs examined, the
values provided by the two independent methods were
somewhat variable, but showed a very good correlation
(see Table 1, rows 2 and 3). In order to examine the
relationship between these values and the corresponding
multidrug transporter interaction data, we compiled these
values for all TKIs examined in this study. In Table 1, we
present all these data by sorting according to the ascending
Kowwin hydrophobicity values.
As documented in Table 1, while the two different
estimations for the hydrophobicity values are in good
correlation, the values obtained for the interaction of TKIs
with either the MDR1 or the MRP1 protein show no
apparent correlation with these parameters. The only appre-
ciable information provided by this comparison is that no
MDR1-interacting compounds were found with low hydro-
phobicity values (below Kowwin 1.29), while in the case of
MRP1, even this relationship was absent.
4. Discussion
TKIs are among the most important drug candidates in
the area of signal transduction therapy, fighting cancer and
other proliferative diseases [33–35]. Beside the success-
story of STI-571 against chronic myelogenous leukemia, at
present, there are several TKIs at various stages of clinical
trials [4,5]. TKIs not only inhibit the proliferation of tumor
cells, but also induce programmed cell death, which con-
tribute to their therapeutic significance [36,37]. These inhib-
itors in most cases have to reach their intracellular targets,
therefore membrane transport mechanisms significantly
alter their effectiveness and inhibitory potential. Active
transport mechanisms, mostly based on the functioning of
multidrug transporter proteins, may be major players in
modifying their cellular action.
The major multidrug transporters, MDR1 and MRP1, are
involved in cancer drug resistance by extruding a large
variety of hydrophobic compounds. In the case of MRP1,
this is supplemented with the outward transport of already
partially detoxified drugs (drug conjugates) from the tumor
cells. In mammals, ABC transporters, like MDR1 and
MRP1, have a key physiological role in the functioning of
the blood–brain and blood–testis barriers, as well as the
kidney, liver, lung, and intestinal epithelial cells. MDR1 is
expressed normally on apical membranes of cells derived
from excretory tissues, as well as on the luminal surface of
cerebral capillary cells [38,39]. MDR1 and MRP1 are
present in the epithelia of the choroid plexus (CP) and both
transporters participate in the blood–CSF permeation bar-
rier [38]. MDR1-Pgp contributes to the drug-permeation
barrier in cerebral capillary endothelial cells and takes part
in elimination of organic cations and xenobiotics from the
Fig. 4. Inhibition of the NEM-GS-stimulated human MRP1-ATPase activity
by various concentrations of TKIs. Maximum activation (100%) was
obtained with 5 mM NEM-GS. Data compiled from at least four
independent measurements for each compound.
Fig. 5. Inhibition of Calcein AM extrusion by the human MDR1 by various
concentrations of TKIs. Calcein AM extrusion was measured in HL-60
MDR1 cells (see Experimental procedures). Data compiled from at least
four independent measurements for each compound.
Fig. 6. Inhibition of Calcein AM and free Calcein extrusion by the human
MRP1 by various concentrations of TKIs. Calcein AM extrusion was
measured in HL-60 MRP1 cells. Data compiled from at least four
independent measurements for each compound.
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central nervous system (CNS) [40,41]. MRP1 contributes to
the basolateral broad-specificity drug-permeation barrier in
CP, protects this epithelium from xenobiotics and extrudes
organic anions and probably also some hydrophobic com-
pounds from the CSF [42].
Drugs interacting with the multidrug transporter proteins
may be useful for the reversal of cancer drug resistance, as
well as for increasing the absorption, or the brain entry of
various pharmacological agents (for review see [Ref. 43]).
In the case of new anticancer agents, it is exceptionally
important to obtain an estimate for their potential interaction
with the multidrug transporter proteins, as such interactions
will alter the anticancer activity and tissue distribution of the
given drug.
In the present paper, we have shown that, by using
relatively simple isolated membrane and whole-cell assays
for analyzing the function of the multidrug transporters, it is
possible to quantitatively examine the interactions of TKIs
with these proteins. Here we applied the measurement of
specific ATPase activity and Calcein extrusion function of
the multidrug transporters for this analysis.
A few interesting examples of the TKIs examined here
are worth discussing. One such molecule is STI-571, a
specific inhibitor of the Bcr–Abl tyrosine kinase, which is
already in wide-range clinical trials. Our data presented here
indicate that STI-571 is an actively transported substrate of
the human MDR1 P-glycoprotein, as STI-571 activates the
MDR1-ATPase at low micromolar concentrations and inter-
feres with MDR1-dependent active Calcein AM extrusion.
The dual action of STI-571 on the MDR1-ATPase activity is
similar to many drugs examined earlier, that is in higher
concentration, a self-inhibition is observed. The exact sig-
nificance of this phenomenon is not clear, but Cyclosporin
A is a prototype compound with a similar MDR1-interaction
[44]. In contrast to MDR1, STI-571 does not seem to be a
good substrate or inhibitor of the human MRP1 protein.
These data suggest that the clinical action of STI-571 may
be significantly inhibited in MDR1-P glycoprotein express-
ing tumors, while no such interference should be expected
in MRP1-expressing cancer tissues.
For another lead compound in preclinical and clinical
trials, EKI-785, we found an opposite situation. This mol-
ecule does not seem to interact with MDR1 in the in vivo
relevant micromolar concentration range. However, EKI-
785 seems to specifically interact with the human MRP1
protein. This compound inhibits the MRP1-dependent Cal-
cein transport and also inhibits the NEM-GS stimulated
MRP1-ATPase activity. In order to explore the interaction of
EKI-785 with MRP1, further transport and ATPase studies
would be required. Especially, the interaction (ATPase
activation) of this compound with MRP1 should be inves-
tigated in detail at various concentrations of free GSH, in
order to establish if EKI-785 is a high-affinity actively
transported substrate of MRP1.
When examining the data in Table 1, another few exam-
ples are also worth mentioning. It is quite obvious that TRX-
13, a prospective clinically applicable compound has no
apparent interaction with the multidrug transporters exam-
ined here, which may make this compound an important tool
in the case of multidrug-resistant cancers. In contrast, when
further developing AG-1393 or its derivatives, a major
concern could be their high-affinity interactions with both
MDR1 and MRP1. OL-57 or OBF-1822 are on the border-
line of interacting with the multidrug transporters, thus each
newly developed modifications of these lead compounds
should be individually examined in this regard.
In numerous cases, the potential tissue distribution,
blood–brain barrier penetration, or interaction with multi-
drug transporter proteins for a given lead compound is
estimated based on molecular hydrophobicity parameters.
An important message of the present study is that this
estimation may be entirely misleading. As documented in
Table 1, compounds with similar high hydrophobicity, like
AG-1393 and TRX-13 may have an entirely different
interaction pattern with both MDR1 and MRP1. Since these
proteins are also major players in the blood–brain barrier,
both penetration into the CNS and anticancer effects in
multidrug-resistant tumors should be entirely different for
these compounds.
We should emphasize in this discussion, that the current,
relatively simple studies for the TKI molecules with the
multidrug transporters provide only a basic information for
these interaction patterns. When these measurements indi-
cate a positive interaction, the evaluation of each lead
compound should be extended to cellular drug-resistance
and direct transport experiments, as we have done previ-
ously for the small hydrophobic peptide derivatives devel-
oped in our laboratory [32].
5. Conclusions
As a summary, in the present study, we found that several
TKIs examined show a direct interaction with MDR1 and
MRP1, although with a large variability in the transporter
selectivity and specificity. This interaction does not directly
correlate with the hydrophobicity or molecular structure of
TKIs, thus the interactions cannot be correctly predicted on
the basis of these parameters. We suggest that high-through-
put enzyme- and cell-based interaction tests with the multi-
drug transporters should facilitate drug development, and
allow the prediction of clinical TKI resistance based on this
mechanism. We also suggest that pretreatment diagnostics
for the expression of specific multidrug transporters in the
malignant cells will allow a more effective, individualized
clinical treatment for the cancer patients.
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